Epidemiology, diagnostics and factors associated with mortality during a cholera epidemic in Nigeria, October 2020-October 2021: a retrospective analysis of national surveillance data.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
19 09 2022
Historique:
entrez: 19 9 2022
pubmed: 20 9 2022
medline: 23 9 2022
Statut: epublish

Résumé

Nigeria reported an upsurge in cholera cases in October 2020, which then transitioned into a large, disseminated epidemic for most of 2021. This study aimed to describe the epidemiology, diagnostic performance of rapid diagnostic test (RDT) kits and the factors associated with mortality during the epidemic. A retrospective analysis of national surveillance data. 33 of 37 states (including the Federal Capital Territory) in Nigeria. Persons who met cholera case definition (a person of any age with acute watery diarrhoea, with or without vomiting) between October 2020 and October 2021 within the Nigeria Centre for Disease Control surveillance data. Attack rate (AR; per 100 000 persons), case fatality rate (CFR; %) and accuracy of RDT performance compared with culture using area under the receiver operating characteristic curve (AUROC). Additionally, individual factors associated with cholera deaths and hospitalisation were presented as adjusted OR with 95% CIs. Overall, 93 598 cholera cases and 3298 deaths (CFR: 3.5%) were reported across 33 of 37 states in Nigeria within the study period. The proportions of cholera cases were higher in men aged 5-14 years and women aged 25-44 years. The overall AR was 46.5 per 100 000 persons. The North-West region recorded the highest AR with 102 per 100 000. Older age, male gender, residency in the North-Central region and severe dehydration significantly increased the odds of cholera deaths. The cholera RDT had excellent diagnostic accuracy (AUROC=0.91; 95% CI 0.87 to 0.96). Cholera remains a serious public health threat in Nigeria with a high mortality rate. Thus, we recommend making RDT kits more widely accessible for improved surveillance and prompt case management across the country.

Identifiants

pubmed: 36123095
pii: bmjopen-2022-063703
doi: 10.1136/bmjopen-2022-063703
pmc: PMC9486350
doi:

Substances chimiques

Reagent Kits, Diagnostic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e063703

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Bull World Health Organ. 2012 Mar 1;90(3):209-218A
pubmed: 22461716
J Water Health. 2003 Mar;1(1):45-52
pubmed: 15384272
J Hyg (Lond). 1983 Aug;91(1):101-11
pubmed: 6886407
PLoS One. 2012;7(5):e36930
pubmed: 22662131
Pan Afr Med J. 2018 May 04;30:5
pubmed: 30123408
Vaccine. 2018 Dec 14;36(51):7759-7764
pubmed: 29802002
Pan Afr Med J. 2020 Dec 22;37:368
pubmed: 33796181
J Clin Microbiol. 1992 Oct;30(10):2730-2
pubmed: 1400976
J Clin Microbiol. 2016 Oct;54(10):2618-21
pubmed: 27487957
PLoS One. 2015 Aug 18;10(8):e0135676
pubmed: 26284367
PLoS One. 2012;7(5):e37360
pubmed: 22666350
J Health Popul Nutr. 2013 Jun;31(2):178-84
pubmed: 23930335
BMC Public Health. 2014 Nov 16;14:1167
pubmed: 25399402
BMJ Glob Health. 2019 Jul 3;4(4):e001427
pubmed: 31354972
PLoS Negl Trop Dis. 2013;7(2):e2049
pubmed: 23459673
Pan Afr Med J. 2012;12:59
pubmed: 22937199
BMC Public Health. 2019 Sep 13;19(1):1264
pubmed: 31519163
BMC Public Health. 2020 Apr 3;20(1):432
pubmed: 32245445
BMC Public Health. 2019 Jan 25;19(1):112
pubmed: 30683078
Int J Public Health. 2021 Jun 15;66:1604030
pubmed: 34744594
Rev Sci Tech. 2005 Dec;24(3):825-32
pubmed: 16642753
West Afr J Med. 2013 Jul-Sep;32(3):173-9
pubmed: 24122681

Auteurs

Kelly Elimian (K)

Nigeria Centre for Disease Control, Abuja, Nigeria kelly.elimian@ki.se.
Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.

Sebastian Yennan (S)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Anwar Musah (A)

Department of Risk and Disaster Reduction, University College London, London, UK.

Iliya Danladi Cheshi (ID)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Carina King (C)

Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.

Lauryn Dunkwu (L)

Tony Blair Institute for Global Change, London, UK.

Ahmed Ladan Mohammed (AL)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Eme Ekeng (E)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Oluwatosin Wuraola Akande (OW)

Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria.

Stephanie Ayres (S)

Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.

Benjamin Gandi (B)

Bauchi State Ministry of Health, Bauchi, Nigeria.

Emmanuel Pembi (E)

Adamawa State Ministry of Health, Yola, Nigeria.

Fatima Saleh (F)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Ahmed Nasir Omar (AN)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Emily Crawford (E)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Olubunmi Omowumi Olopha (OO)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Robinson Nnaji (R)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Basheer Muhammad (B)

Kano State Ministry of Health, Kano, Nigeria.

Rejoice Luka-Lawal (R)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Adachioma Chinonso Ihueze (AC)

Georgetown University, Abuja, Nigeria.

David Olatunji (D)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Chidimma Ojukwu (C)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Afolabi Muftau Akinpelu (AM)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Ene Adaga (E)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Yusuf Abubakar (Y)

Zamfara State Ministry of Health, Zamfara State, Nigeria.

Ifeoma Nwadiuto (I)

Rivers State Ministry of Health, Port Harcourt, Nigeria.

Samuel Ngishe (S)

Public Health, Ministry of Health, Benue State, Makurdi, Nigeria.

Agnes Bosede Alowooye (AB)

Ekitit State Ministry of Health and Human Services, Ado-Ekiti, Nigeria.

Peace Chinma Nwogwugwu (PC)

Abia State Ministry of Health, Umuanhia, Nigeria.

Khadeejah Kamaldeen (K)

Kwara State Ministry of Health, Ilorin, Nigeria.

Henry Nweke Abah (HN)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Egbuna Hyacinth Chukwuebuka (EH)

Imo State Ministry of Health, Owerri, Nigeria.

Hakeem Abiola Yusuff (HA)

Ogun State Ministry of Health, Abeokuta, Nigeria.

Ibrahim Mamadu (I)

World Health Organization Country Office for Nigeria, Abuja, Nigeria.

Abbas Aliyu Mohammed (AA)

Ministry of Health, Sokoto State, Sokoto, Nigeria.

Sarah Peter (S)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Okpachi Christopher Abbah (OC)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Popoola Michael Oladotun (PM)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Santino Oifoh (S)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Micheal Olugbile (M)

World Bank Nigeria Office, Abuja, Nigeria.

Emmanuel Agogo (E)

Resolve to Saves Lives, Abuja, Nigeria.

Nnaemeka Ndodo (N)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Olajumoke Babatunde (O)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Nwando Mba (N)

Nigeria Centre for Disease Control, Abuja, Nigeria.

John Oladejo (J)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Elsie Ilori (E)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Tobias Alfvén (T)

Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.

Puja Myles (P)

Clinical Practice Research Datalink, London, UK.

Chinwe Lucia Ochu (CL)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Chikwe Ihekweazu (C)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Ifedayo Adetifa (I)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH